MTOR and cancer: Furthermore, AMPK inhibits IRS1 mediated IR and IGFR oncogenic signaling via PI3K/Akt/mTOR, which, potentially, also contributes to the anti-cancer effect of metformin (Figure 2) [69,70,71].